Friday, October 2, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleNasdaq· February 17, 2026

Stocks Retreat on AI Anxiety

View original at nasdaq.com
Stocks Retreat on AI Anxiety The S&P 500 Index ($SPX) (SPY) today is down -0.27%, the Dow Jones Industrial Average ($DOWI) (DIA) is down -0.22%, and the Nasdaq 100 Index ($IUXX) (QQQ) is down -0.51%…
Opening lines of the source · Nasdaq · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Full-year organic net sales forecast to be down 1.5% to 2.0%, reduced from previous forecast of -1% to +1%

    80% confidence
  • Elliott Investment Management has built a more than 10% stake in Norwegian Cruise Line

    80% confidence
  • Southwest Airlines upgraded to buy from neutral with $73 price target

    80% confidence
  • S&P earnings growth expected to climb by 8.4% in Q4, marking the tenth consecutive quarter of year-over-year growth

    80% confidence
  • Excluding the Magnificent Seven megacap technology stocks, Q4 earnings expected to increase by 4.6%

    80% confidence
  • AeroVironment rated overweight with $320 price target

    80% confidence
  • Activist investor Jana Partners has built a stake in Fiserv and is pushing for changes to improve stock performance

    80% confidence
  • Services inflation remains elevated, but there is potential for more interest rate cuts this year if inflation continues to return to the Fed's 2% target

    80% confidence
  • Danaher is closing in on a nearly $10 billion deal to acquire Masimo

    80% confidence
  • Full-year adjusted Ebitda forecast at $2.4 billion to $2.6 billion

    80% confidence
  • Warner Bros Discovery is considering reopening sale talks with Paramount Skydance

    80% confidence
  • 2026 adjusted EPS forecast at $8.70 to $9.90

    80% confidence
  • Full-year adjusted EPS forecast at $5.62 to $5.66

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI-Driven Drug Development Meets Biotech Deal-Making and Regulatory Catalysts
AI-designed therapeutics (Insilico's rentosertib showing biological-age reductions) are moving into the clinical mainstream. Large-cap biotech is simultaneously reallocating capital through M&A (Lilly–Merida, $2.9B) and government funding (BARDA–Basilea), while trial failures (ziltivekimab, a 9.4% Novo Nordisk share drop) and upcoming FDA catalysts (the ivonescimab PDUFA on 2026-11-14) drive volatility. The wider AI regulatory and legal climate (Tesla Cybercab probe, xAI's Minnesota loss, OpenAI suits) is tightening, though QAIAx's micro-cap trial claims are speculative and weakly connected.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,327 source documents archived
Query this data → isubstrate.com